Development of targeted oncolytic virotherapeutics through translational research.
BACKGROUND
Oncolytic virotherapeutics is a promising platform for cancer treatment but the product class has yet been successful. The key to success is integration of bidirectional translational research to rapidly address issues encountered in the laboratory and the clinics.


OBJECTIVE
We highlight the hurdles identified for the targeted oncolytic virotherapy approach, specifically those identified in clinical trials with wild-type viruses and first-generation targeted agents. We also analyze the translational research and development that has been applied to overcome these hurdles, including virus engineering and design improvements for next-generation virotherapeutics.


CONCLUSIONS
The iterative loop between the clinic and the lab can function as a major driving force to optimize products from this platform.
Liu
Ta-Chiang
TC
Jennerex Biotherapeutics, One Market Street, Spear Tower, Suite 2260, San Francisco, CA 94105, USA.
Hwang
Tae-Ho
TH
Bell
John C
JC
Kirn
David H
DH
D002986:Clinical Trials as Topic; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D050130:Oncolytic Virotherapy; D014176:Protein Biosynthesis